Novartis says Kesimpta gets EU approval in multiple sclerosis

FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company’s headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau

ZURICH (Reuters) – Novartis AG said on Tuesday Kesimpta (ofatumumab) has won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.

The Swiss drugmaker is developing and marketing the product under a license agreement with Genmab.

Source: Read Full Article

Previous post CDC official on hospital pandemic surveillance: 'Minimize manual processes'
Next post Meet Newborn Grace! Bindi Irwin's Pregnancy Chronicled in Discovery+ Special Crikey! It's a Baby